Utilizing Immunoglobulin Replacement Therapy to Improve Clinical and Economic Outcomes in the Management of Primary Immunodeficiency Diseases (PIDD)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
CSL Behring

Primary immunodeficiency diseases (PIDD) are a group of more than 300 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly. While not contagious, these diseases are caused by hereditary or genetic defects however they all share one common feature: each result from a defect in one of the functions of the body's normal immune system. The primary treatment for these patients with antibody deficiencies is lifetime administration of immunoglobulin (Ig) replacement therapy; a therapeutic substance derived from human blood plasma and made up of immunoglobulin. Ig replacement is usually necessary for the patient’s lifetime since therapy only replaces the missing end product and does not correct the patient’s defect in antibody production. Although approximately 150,000 patients are likely to benefit from Ig replacement, only an estimated 35,000 to 55,000 receive ongoing therapy. A lack of awareness and depth of understanding contribute to this underserved population of individuals with PI.

Upon completion of this activity, participants will be able to:

  • Identify patients who may have a primary immunodeficiency disease (PIDD) and discuss appropriate tests to diagnose the disease

  • Examine the history of immunoglobulin (Ig) therapy in PIDD and its rationale for use

  • Compare and contrast the different immunoglobulin products and their FDA-approved indications, sodium and sugar contents, and adverse effects

  • Differentiate the key differences between subcutaneous and intravenous therapy, including the advantages and disadvantages of both options in various patient populations

  • Analyze key pharmacoeconomic studies pertaining to Ig replacement therapy and the budgetary implications of these data in a managed care framework

  • Apply methods to enable optimal cost management of Ig replacement therapies to be realized by multiple PIDD stakeholders including managed care organizations

Faculty: Jennifer Leiding, MD
Associate Professor
Division of Allergy and Immunology
USF Department of Pediatrics
Children’s Research Institute


Dr. Leiding serves on an advisory board for CSL Behring and Horizon Pharma. She serves as a consultant for CSL Behring and Horizon Pharma. She has received grant/research support from Horizon Pharma. She serves on the speaker's bureau for CSL Behring and Horizon Pharma. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue